Id |
Subject |
Object |
Predicate |
Lexical cue |
T14 |
0-228 |
Sentence |
denotes |
The entire virus particle-based preparation of vaccines, including inactivated and attenuated virus vaccines is advisable, because it is based on previous studies about the prevention and control of seasonal influenza vaccines6. |
T15 |
229-369 |
Sentence |
denotes |
The first SARS-CoV-2 (Wuhan-Hu-1) was successfully sequenced and its genomic sequence submitted to GenBank on January 5, 2020 (Accession no. |
T16 |
370-383 |
Sentence |
denotes |
MN908947.3)7. |
T17 |
384-626 |
Sentence |
denotes |
Subsequently large-scale culture of SARS-CoV-2 was quickly performed, and an inactivated virus vaccine could be prepared through the employment of established physical and chemical methods such as UV light, formaldehyde, and β-propiolactone8. |
T18 |
627-936 |
Sentence |
denotes |
The development of attenuated-virus vaccines is also possible by carefully screening the serially propagated SARS-CoV-2 with reduced pathogenesis such as induced minimal lung injury, diminished limited neutrophil influx, and increased anti-inflammatory cytokine expressions compared with the wild-type virus9. |
T19 |
937-1040 |
Sentence |
denotes |
Both inactivated and attenuated virus vaccines have their own disadvantages and side effects (Table 1). |
T20 |
1041-1171 |
Sentence |
denotes |
Alternatively, new vaccine designs based on the putative protective antigen/peptides derived from SARS-CoV-2 should be considered. |
T21 |
1172-1241 |
Sentence |
denotes |
Table 1 Advantages and disadvantages of different vaccine strategies. |
T22 |
1242-1294 |
Sentence |
denotes |
Vaccine strategy Advantages Disadvantages References |
T23 |
1295-1448 |
Sentence |
denotes |
Inactivated virus vaccines Easy to prepare; safety; high-titer neutralizing antibodies Potential inappropriate for highly immunosuppressed individuals 25 |
T24 |
1449-1598 |
Sentence |
denotes |
Attenuated virus vaccines Rapid development; induce high immune responses Phenotypic or genotypic reversion possible; can still cause some disease 25 |
T25 |
1599-1812 |
Sentence |
denotes |
Subunit vaccines High safety; consistent production; can induce cellular and humoral immune responses; high-titer neutralizing antibodies High cost; lower immunogenicity; require repeated doses and adjuvants 12,14 |
T26 |
1813-1935 |
Sentence |
denotes |
Viral vector vaccines Safety; induces high cellular and humoral immune responses Possibly present pre-existing immunity 12 |
T27 |
1936-2085 |
Sentence |
denotes |
DNA vaccines Easier to design; high safety; high-titer neutralizing antibodies Lower immune responses in humans; repeated doses may cause toxicity 23 |
T28 |
2086-2227 |
Sentence |
denotes |
mRNA vaccines Easier to design; high degree of adaptability; induce strong immune responses Highly unstable under physiological conditions 23 |